Fitch projects tepid revenue growth for drugmakers; Abbott spanked for ad campaign targeted at kids;

@FiercePharma: Trending now: Think Fast: New cognition study could add $350M to Lundbeck's Brintellix sales. Yesterday's story | Follow @FiercePharma

@EricPFierce: Merck KGaA sees upside in allergy meds, emerging markets. New plant to make allergy meds 4 emerging markets. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Good news for Vivus: Sanofi has signed on to sell ED drug Stendra in emerging markets. Release | Follow @CarlyHFierce

> Novartis ($NVS) is recalling some batches of its children's Tixylix liquid cough and cold medicines in the U.K. because of a potential manufacturing defect that could result in small pieces of plastic being found in the bottles. Story

> AstraZeneca ($AZN) intends to spend about $100 million over 5 years on upgrades to a distribution site in Delaware. Blog post

> Ratings agency Fitch is projecting that the revenues of branded drugmakers will rise just 2% to 3% next year. Story

> Prescription drug spending in Canada has fallen on a per-capita basis over the last 5 years, but that trend is expected to change soon. Story

> Drugmakers in India have failed to reach an agreement with drug distributors and retailers on the margins of price-controlled medicines, complicating the new policy that is to take effect next year. Story

Medical Device News

@FierceMedDev: Chutes & Ladders this week: Merck's Kim resigns to teach at Stanford med school. Feature | Follow @FierceMedDev

@MarkHFierce:  Quest Diagnostics improved the lower-end of its 2013 earnings expectations, but still says overall revenue will dip. Story | Follow @MarkHFierce

@MichaelGFierce: Brain implant recovers motor function by boosting neuron communication. Item | Follow @MichaelGFierce

@GalenMoore: Researchers say they've synthesized erythropoietin, a hormone used for doping. More via Nature | Follow @GalenMoore

> Roche pairs Ventana breast cancer test with two more of its blockbuster drugs. News

> Brain implant recovers motor function by boosting neuron communication. Article

> Silver service: S&N's Durafiber Ag now dresses European wounds, too. Piece

> Device IDs: Med tech industry wants FDA to fine-tune the rule. More

Biotech News

@FierceBiotech: Genzyme's Lemtrada has been approved in Canada for treatment of multiple sclerosis. Release | Follow @FierceBiotech

@JohnCFierce: Trending: Why did Roche kill off its Alzheimer's program for the BACE inhibitor RG7129? Editor's corner | Follow @JohnCFierce

@DamianFierce: AVEO says tivozanib's colorectal cancer data isn't looking good, taking another ~15% off its already ailing shares. Story | Follow @DamianFierce

@EmilyMFierce: Report: Life science research needs standards to curb irreproducible studies. Story from FierceBiotech Research | Follow @EmilyMFierce

> Merck's allergy pill clears an FDA hurdle, but efficacy questions linger. Story

> FDA panel smiles on Bristol-Myers, AstraZeneca's diabetes drug in do-over. More

> AstraZeneca gets some good news for its late-stage gout therapy. Article

> Bill would fast-track promising antibiotics for FDA approval. News

> AbbVie's veliparib wows in a breast cancer study. Item

And Finally... Abbott Laboratories ($ABT) recently settled a case with the New York Attorney General over allegations that its "You Are What You Eat" advertising campaign for its Pediasure Sidekicks products inappropriately presented the message that children who consumed the products performed better than children who did not. Story

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.